Given that IL-6 is a critical driver of inflammatory amplification, osteoclast activation, and immune cell recruitment, its reduction further highlights the therapeutic potential of these interventions in modulating the broader cytokine cascade and mitigating RA-associated joint pathology. This evidence concerns the gene IL6 and rheumatoid arthritis.